These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 3174541)
1. Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate. Tan TT; Alzaid AA; Sutcliffe N; Gardner MD; Thomson JA; Boyle IT Postgrad Med J; 1988 Mar; 64(749):224-7. PubMed ID: 3174541 [TBL] [Abstract][Full Text] [Related]
2. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin. Ralston SH; Alzaid AA; Gardner MD; Boyle IT Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513 [TBL] [Abstract][Full Text] [Related]
3. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer. Cantwell BM; Harris AL Br Med J (Clin Res Ed); 1987 Feb; 294(6570):467-9. PubMed ID: 3103730 [TBL] [Abstract][Full Text] [Related]
4. Single high dose aminohydroxypropylidene diphosphonate infusions to treat cancer-associated hypercalcaemia. Cantwell B; Harris AL Lancet; 1986 Jan; 1(8473):165-6. PubMed ID: 2867388 [No Abstract] [Full Text] [Related]
5. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417 [TBL] [Abstract][Full Text] [Related]
6. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy. McIntyre HD; Cameron DP; Urquhart SM; Davies WE Postgrad Med J; 1989 Apr; 65(762):244-6. PubMed ID: 2594602 [TBL] [Abstract][Full Text] [Related]
7. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia. Sawyer N; Newstead C; Drummond A; Cunningham J Bone Miner; 1990 May; 9(2):121-8. PubMed ID: 2350615 [TBL] [Abstract][Full Text] [Related]
8. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy. Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925 [TBL] [Abstract][Full Text] [Related]
9. Abdominal symptoms, hypercalcaemia and apathetic hyperthyroidism: treatment with pamidronate. Ghose RR; Palmer DJ; Yaqoob M; Haboubi N; Ratcliffe WA Br J Clin Pract; 1994; 48(3):163-4. PubMed ID: 8031697 [TBL] [Abstract][Full Text] [Related]
10. Aminohydroxypropylidene diphosphonate treatment of hypercalcemic crisis due to primary hyperparathyroidism. Evans RA Aust N Z J Med; 1987 Feb; 17(1):58-9. PubMed ID: 3476049 [TBL] [Abstract][Full Text] [Related]
11. Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia. Mannix KA; Carmichael J; Harris AL; Cantwell BM Cancer; 1989 Sep; 64(6):1358-61. PubMed ID: 2766228 [TBL] [Abstract][Full Text] [Related]
12. Treatment of refractory cancer-associated hypercalcemia with aminohydroxypropylidene diphosphonate. Heaf JG; Hansen M Acta Med Scand; 1988; 224(3):287-8. PubMed ID: 3239457 [TBL] [Abstract][Full Text] [Related]
14. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia. Ralston SH; Alzaid AA; Gallacher SJ; Gardner MD; Cowan RA; Boyle IT Q J Med; 1988 Oct; 68(258):825-34. PubMed ID: 3268894 [TBL] [Abstract][Full Text] [Related]
15. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism. Tal A; Graves L South Med J; 1996 Jun; 89(6):637-40. PubMed ID: 8638211 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of aminohydroxypropylidene diphosphonate in the treatment of malignancy-associated hypercalcaemia. Stevens MJ Med J Aust; 1987 Mar; 146(5):261-4. PubMed ID: 3821622 [TBL] [Abstract][Full Text] [Related]
17. Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia. Sleeboom HP; Bijvoet OL; van Oosterom AT; Gleed JH; O'Riordan JL Lancet; 1983 Jul; 2(8344):239-43. PubMed ID: 6135076 [TBL] [Abstract][Full Text] [Related]
18. Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient. Varache N; Audran M; Clochon P; Lortholary A; Bouachour G; Alquier P; Basle MF Clin Rheumatol; 1991 Sep; 10(3):328-32. PubMed ID: 1790647 [TBL] [Abstract][Full Text] [Related]
19. Vitamin D intoxication and hypercalcaemia in an infant treated with pamidronate infusions. Ezgu FS; Buyan N; Gündüz M; Tümer L; Okur I; Hasanoglu A Eur J Pediatr; 2004 Mar; 163(3):163-5. PubMed ID: 14714183 [TBL] [Abstract][Full Text] [Related]
20. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy. Davis JR; Heath DA Br J Clin Pharmacol; 1989 Sep; 28(3):269-74. PubMed ID: 2789920 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]